Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
OGX-225
print preview
bookmark
share with colleague
General Information
Company
OncoGenex Pharmaceuticals Inc.
Description
Second-generation antisense inhibitor of insulin-like growth factor-2 (IGF-2) receptor (IGF2R) and insulin-like growth factor (IGF) binding protein 5 (IGFBP5)
Molecular Target
Insulin-like growth factor (IGF) binding protein 2 (IGFBP2)
;
Insulin-like growth factor (IGF) binding protein 5 (IGFBP5)
Mechanism of Action
Antisense therapy
Latest Stage of Development
Preclinical
Indication
Solid tumors
Partner
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy